The newly reconstituted Immunomedics board is likely to start a search for a new CEO and could either renegotiate the IMMU-132 deal with Seattle Genetics or cancel it. Immunomedics shareholders elected Friday to install an activist slate of four new directors, bringing to a close a protracted fight for control of the biotech company.